Results
Revise Search
-
Filters:
- All Records
- 1973
- 2017
- 1987
- Policy resolution
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Opioid overdose prevention supplies available in publicly accessible locations
https://policybase.cma.ca/en/permalink/policy13703
- Date
- 2017-08-23
- Topics
- Health care and patient safety
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Resolution
- GC17-06
- The Canadian Medical Association supports making naloxone and other opioid overdose prevention supplies available in publicly accessible locations.
- Policy Type
- Policy resolution
- Date
- 2017-08-23
- Resolution
- GC17-06
- The Canadian Medical Association supports making naloxone and other opioid overdose prevention supplies available in publicly accessible locations.
- Text
- The Canadian Medical Association supports making naloxone and other opioid overdose prevention supplies available in publicly accessible locations.
Management of chronic pain in older adults
https://policybase.cma.ca/en/permalink/policy13705
- Date
- 2017-08-23
- Topics
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Resolution
- GC17-07
- The Canadian Medical Association supports increased approval and funding of pharmacologic options for the management of chronic pain in older adults.
- Policy Type
- Policy resolution
- Date
- 2017-08-23
- Resolution
- GC17-07
- The Canadian Medical Association supports increased approval and funding of pharmacologic options for the management of chronic pain in older adults.
- Text
- The Canadian Medical Association supports increased approval and funding of pharmacologic options for the management of chronic pain in older adults.
Antimicrobial stewardship and antimicrobial resistance surveillance
https://policybase.cma.ca/en/permalink/policy13710
- Date
- 2017-08-23
- Topics
- Health care and patient safety
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Resolution
- GC17-11
- The Canadian Medical Association calls on the federal government to use Canada’s term as G7 President in 2018 to add antimicrobial stewardship and antimicrobial resistance surveillance as part of their agenda.
- Policy Type
- Policy resolution
- Date
- 2017-08-23
- Resolution
- GC17-11
- The Canadian Medical Association calls on the federal government to use Canada’s term as G7 President in 2018 to add antimicrobial stewardship and antimicrobial resistance surveillance as part of their agenda.
- Text
- The Canadian Medical Association calls on the federal government to use Canada’s term as G7 President in 2018 to add antimicrobial stewardship and antimicrobial resistance surveillance as part of their agenda.
Psycho-active substances and the operation of motor vehicles and industrial equipment
https://policybase.cma.ca/en/permalink/policy781
- Last Reviewed
- 2017-03-04
- Date
- 1973-06-16
- Topics
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Population health/ health equity/ public health
- Resolution
- GC73-50
- That the membership of the Canadian Medical Association clearly inform its patients, and the general public at large, of the hazards associated with the operation of motor vehicles, industrial equipment, etc., while under the influence of psycho-active substances, especially alcohol and antihistamines, and particularly the combination of such substances.
- Policy Type
- Policy resolution
- Last Reviewed
- 2017-03-04
- Date
- 1973-06-16
- Topics
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Population health/ health equity/ public health
- Resolution
- GC73-50
- That the membership of the Canadian Medical Association clearly inform its patients, and the general public at large, of the hazards associated with the operation of motor vehicles, industrial equipment, etc., while under the influence of psycho-active substances, especially alcohol and antihistamines, and particularly the combination of such substances.
- Text
- That the membership of the Canadian Medical Association clearly inform its patients, and the general public at large, of the hazards associated with the operation of motor vehicles, industrial equipment, etc., while under the influence of psycho-active substances, especially alcohol and antihistamines, and particularly the combination of such substances.
Adverse reactions between alcohol and drug products
https://policybase.cma.ca/en/permalink/policy805
- Last Reviewed
- 2017-03-04
- Date
- 1987-08-25
- Topics
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Resolution
- GC87-31
- That the Canadian Medical Association urge appropriate agencies to adopt regulations and/or policies to ensure that warnings about the adverse interaction between alcohol and both prescription and non-prescription products be prominently displayed or distributed wherever alcohol and drugs are sold and/or dispensed.
- Policy Type
- Policy resolution
- Last Reviewed
- 2017-03-04
- Date
- 1987-08-25
- Resolution
- GC87-31
- That the Canadian Medical Association urge appropriate agencies to adopt regulations and/or policies to ensure that warnings about the adverse interaction between alcohol and both prescription and non-prescription products be prominently displayed or distributed wherever alcohol and drugs are sold and/or dispensed.
- Text
- That the Canadian Medical Association urge appropriate agencies to adopt regulations and/or policies to ensure that warnings about the adverse interaction between alcohol and both prescription and non-prescription products be prominently displayed or distributed wherever alcohol and drugs are sold and/or dispensed.
Drug product substitution
https://policybase.cma.ca/en/permalink/policy806
- Last Reviewed
- 2017-03-04
- Date
- 1987-08-25
- Topics
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Resolution
- GC87-39
- The Canadian Medical Association supports the position that: 1) a patient should have the right to choose either a generic or a brand-name prescription drug where both alternatives exist; and 2) a physician should have the right to order "no substitution" of a drug product he or she prescribes.
- Policy Type
- Policy resolution
- Last Reviewed
- 2017-03-04
- Date
- 1987-08-25
- Resolution
- GC87-39
- The Canadian Medical Association supports the position that: 1) a patient should have the right to choose either a generic or a brand-name prescription drug where both alternatives exist; and 2) a physician should have the right to order "no substitution" of a drug product he or she prescribes.
- Text
- The Canadian Medical Association supports the position that: 1) a patient should have the right to choose either a generic or a brand-name prescription drug where both alternatives exist; and 2) a physician should have the right to order "no substitution" of a drug product he or she prescribes.